Befejeződött2. fázis
PDC-1421 Treatment in Adult Patients With ADHD
A legfontosabb adatok
- Ki végzi
- BioLite, Inc.
- Hol
- San Francisco (Egyesült Államok)A helyszín megnézéseMég 1 másik országban, 5 helyszínen
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 2. fázis
- Résztvevők
- 99 fő vett részt
- Kezdés
- 2022. ápr. 7.
- Befejezés
- 2024. ápr. 8.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- PDC-1421 Capsule
- Placebo
- A regiszteradat frissítve
- 2026. május 6.
Ki vehet részt
- Életkor
- 18 év – 70 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 16 feltétel megnézéseKevesebb
Ki vehet részt
- Aged 18-70 years
- Female subjects of child-bearing potential must test negative to pregnancy and use appropriate birth control method from the beginning of study to the 15 days later after ending of study
- Subjects must be able to understand and willing to sign informed consent
- Able to discontinue the use of any psychotropic medications for the treatment of ADHD symptoms at screening
- Meet strict operational criteria for adult ADHD according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)
- A total score of 28 or higher of ADHD Rating Scale-Investigator Rated (ADHD-RS-IV) at screening
- Have a moderate or severe symptom of ADHD with score of 4 or higher in Clinical Global Impression- Severity (CGI-S) at screening
Ki nem vehet részt
- Have any clinically significant concurrent medical condition (endocrine, renal, respiratory, cardiovascular, hematological, immunological, cerebrovascular, neurological, anorexia, obesity or malignancy) that has become unstable and may interfere with the interpretation of safety and efficacy evaluations
- Have known serological evidence of human immunodeficiency virus (HIV) antibody
- Have current of bipolar and psychotic disorders
- Have a current major depression disorder, obsessive-compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder, panic disorder and eating disorder (also if treated but not currently symptomatic) NOTE: Comorbid diagnoses identified during screening and baseline are acceptable provided that ADHD is the primary diagnosis and the comorbid diagnoses will not confound study data or impair subject's ability to participate (per the Investigator's judgement and documented in source note)
- Have any history of a significant suicide attempt, or possess a current risk of attempting suicide, in the investigator's opinion, based on clinical interview and responses provided on the Columbia-Suicide Severity Rating Scale (C-SSRS)
- Have a history of jailing or imprisonment in the past 6 months due to worsening of symptoms of ADHD
- Have any clinically significant abnormal laboratory, vital sign, physical examination, or electrocardiogram (ECG) findings at screening that, in the opinion of the investigator, may interfere with the interpretation of safety or efficacy evaluations
- Have QTc values >450 msec at screening using Fridericia's QTc formula
- Are pregnant as confirmed by a positive pregnancy test at screening
Helyszínek itt: Egyesült Államok
Még 1 másik országban, 5 helyszínen
- University of California San FranciscoSan Francisco, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
Part II is a double-blind, randomized, parallel-group, placebo-controlled study. The primary objective of this trial is to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD. The secondary objective is to evaluate the safety of PDC-1421 Capsule in subjects receiving PDC-1421 at various dose levels.
A vizsgálat 3 csoportja
- PlaceboPlacebo, összehasonlításként
Two placebo capsules thrice daily for 56 days (8 weeks).
- Low-doseA vizsgált kezelés
One placebo capsule and 1 PDC-1421 Capsule, thrice daily for 56 days (8 weeks).
Kezelés: PDC-1421 Capsule és Placebo
- High-doseA vizsgált kezelés
Two PDC-1421 Capsules thrice daily for 56 days (8 weeks).
Kezelés: PDC-1421 Capsule
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD), Part II
- A regiszteradat frissítve
- 2026. május 6.